EHA 2016: New Therapeutic Strategies for the Management of Patients with Relapsed-Refractory Multiple Myeloma
This CME program will cover data on new therapeutic strategies for the management of patients with relapsed-refractory multiple myeloma that were presented at the European Hematology Association 2016 Annual Congress in Copenhagen, Denmark on June 9 - 12, 2016. The expert faculty of this program will discuss tumor science, including relapsed, refractory, and progressive disease. They will discuss the analysis of clinical trial data and therapy options for the treatment of patients with multiple myeloma. This program will give physicians a better understanding of when to implement data-driven, patient-specific treatment plans to improve outcomes for patients with relapsed or refractory multiple myeloma.
This activity has been designed to meet the educational needs of hematologists/oncologists, and other healthcare professionals who care for patients with multiple myeloma.
Upon completion of this activity, participants will be able to:
- Discuss tumor science or multiple myeloma, including relapsed, refractory, and progressive disease.
- Analyze clinical trial data of emerging stand-alone and/or combination therapy options for the treatment of multiple myeloma presented at EHA 2016.
- Implement data-driven treatment regimens to optimally manage patient-specific disease and improve outcomes for patients with relapsed or refractory multiple myeloma.
C. Ola Landgren, MD, PhD
Rafael Fonseca, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Dr. C Ola Landgren|
Consultant/Advisor: Amgen Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc.
Employment Affiliation: Memorial Sloan Kettering Cancer Center
Dr. Rafael Fonseca
Consultant/Advisor: Amgen Inc.; Bayer Pharma AG; Celgene Corporation; Janssen Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; and Takeda Pharmaceuticals U.S.A., Inc.
Employment Affiliation: FISH Prognostication in Myeloma
Non-faculty: Sandy Breslow; Alison Kemp; Leah Johnson; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Megan Gentile; Nicole Brestowski; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
This CME activity has been supported by an independent educational grant from Amgen Inc.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education (EOCME) is accredited by the Acceditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at firstname.lastname@example.org. Additional information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician